The Rise of Digital Therapeutics

How Digital Therapies Can Help Reimagine Care and Treatment

Report by Rajiv Leventhal  | Apr 12, 2022
Download
Report
Deck
Share
Table of Contents
Executive Summary
Key Points
Digital Therapeutics Find Their Footing in Healthcare
The Opportunity: Assessing the Value of Digital Therapeutics
What Will Determine DTx Success?
Insider Intelligence Interviews
Read Next
Sources
Media Gallery
About This Report
Digital therapeutics (DTx) are becoming more prominent offerings in healthcare. Questions are now arising around which stakeholders will pay for these products and how accessible they’ll be for patients.
Topics
Digital Health
United States
Table of Contents
Executive Summary
Key Points
Digital Therapeutics Find Their Footing in Healthcare
The Opportunity: Assessing the Value of Digital Therapeutics
What Will Determine DTx Success?
Insider Intelligence Interviews
Read Next
Sources
Media Gallery

Executive Summary

Digital therapeutics (DTx) are an emerging category of evidence-based technologies that could disrupt drug development and disease treatment. DTx products have not hit the mainstream and will need to meet a high standard of clinical validation that separates these solutions from the sea of available digital health tools and apps on the market.

3 KEY QUESTIONS THIS REPORT WILL ANSWER

  1. How has the pandemic advanced DTx? 
  2. Why should payers, employers, providers, and drug developers want to invest in DTx now?
  3. What must happen next for DTx tools to become key components of how diseases are managed and treated?

WHAT’S IN THIS REPORT? How DTx solutions differ from typical digital health products and the opportunity they offer, as well as an analysis of the factors that will define success for DTx companies.

Willingness to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians, Oct 2021 (% of respondents)
E-Mail ChartDownload

KEY STAT: US physicians are willing to prescribe DTx to patients based on their clinical efficacy.

Here’s what’s in the full report

2files

Exportable files for easy reading, analysis and sharing.

7charts

Reliable data in simple displays for presentations and quick decision making.

6expert perspectives

Insights from industry and company leaders.

    Table of Contents

    1. Executive Summary
    2. Key Points
    3. Digital Therapeutics Find Their Footing in Healthcare
    1. The Opportunity: Assessing the Value of Digital Therapeutics
    2. What Will Determine DTx Success?
    3. Insider Intelligence Interviews
    1. Read Next
    2. Sources
    3. Media Gallery

    Charts in This Report

    Willingness to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians, Oct 2021 (% of respondents)Specialty Focus Digital Therapeutics Worldwide, June 2021 (% of total)
    Outcomes/Evidence of Efficacy that Are Most Crucial to Making a Prescription Digital Therapeutics (PDTs) Coverage Determination According to US Payers and Employers, Summer 2021 (number of respondents)Level of Trust US Adults Have in Healthcare Digital Tools, by Type, June 2021 (% of respondents)
    US Payers and Employers Who View Prescription Digital Therapeutics (PDTs) as an Effective Tool for Treating Unmet Needs in Select Diseases, Summer 2021 (% of respondents in each group)Top 3 Reasons to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians*, Oct 2021 (% of respondents)
    Digital Technologies That US Adults Have Used to Manage Their Health in the Past Year, by Type, 2016-2021 (% of respondents in each group)

    Interviewed for This Report

    Afsana Akhter
    Amelia Virtual Care
    CEO
    Interviewed March 1, 2022
    Brenda Miao
    Bakar Computational Health Sciences Institute, University of California, San Francisco
    Researcher
    Interviewed February 24, 2022
    Andy Molnar
    Digital Therapeutics Alliance
    CEO
    Interviewed February 17, 2022
    Marissa Schlueter Moore
    OMERS Ventures
    Health Tech Investor
    Interviewed March 2, 2022
    Santosh Shanbhag
    Akili Interactive
    CFO
    Interviewed March 14, 2022
    Chris Wasden
    Happify Health
    Head of Pharma Specialty Solutions and Corporate Strategy
    Interviewed March 3, 2022

    Access full deck

    View a slide-show representation of this report’s key insights, where carefully vetted data is combined with industry trend analysis, included at no extra cost.
    Gain Access to EMARKETER →
    Log in to EMARKETER
    Download PPTX

     

     

     

     

     

     

     

     

     

     

    Access All Charts and Data

    Gain access to reliable data presented in clear and intelligible displays for quick understanding and decision making on the most important topics related to your industry, included at no extra cost.
    Gain Access to EMARKETER →
    Log in to EMARKETER

    authors

    Rajiv Leventhal

    Contributors

    Eleni Digalaki
    Principal Analyst
    Jeane Han
    Senior Researcher
    Lisa Phillips
    Principal Analyst, Digital Health